NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 127 filers reported holding NURIX THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,338,682 | -20.7% | 2,714,845 | +0.8% | 0.00% | 0.0% |
| Q2 2023 | $26,893,490 | +15.4% | 2,692,041 | +2.6% | 0.00% | 0.0% |
| Q1 2023 | $23,296,281 | -3.7% | 2,623,455 | +19.1% | 0.00% | 0.0% |
| Q4 2022 | $24,184,603 | -14.1% | 2,202,605 | +1.9% | 0.00% | 0.0% |
| Q3 2022 | $28,156,000 | +5.2% | 2,160,866 | +2.3% | 0.00% | 0.0% |
| Q2 2022 | $26,754,000 | -5.8% | 2,111,496 | +4.1% | 0.00% | 0.0% |
| Q1 2022 | $28,413,000 | -50.7% | 2,028,063 | +1.9% | 0.00% | 0.0% |
| Q4 2021 | $57,626,000 | -2.8% | 1,990,564 | +0.6% | 0.00% | 0.0% |
| Q3 2021 | $59,259,000 | +52.4% | 1,977,951 | +34.9% | 0.00% | 0.0% |
| Q2 2021 | $38,896,000 | +7.6% | 1,466,137 | +26.1% | 0.00% | 0.0% |
| Q1 2021 | $36,156,000 | +77.9% | 1,162,984 | +88.2% | 0.00% | 0.0% |
| Q4 2020 | $20,320,000 | +8.6% | 617,985 | +15.3% | 0.00% | 0.0% |
| Q3 2020 | $18,716,000 | – | 536,120 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |